- Home
- CSLR vs PBYI Comparison
CSLR vs PBYI Comparison
Compare CSLR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSLR
- PBYI
- Stock Information
- Founded
- CSLR 2022
- PBYI 2010
- Country
- CSLR United States
- PBYI United States
- Employees
- CSLR N/A
- PBYI N/A
- Industry
- CSLR Semiconductors
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- CSLR Technology
- PBYI Health Care
- Exchange
- CSLR Nasdaq
- PBYI Nasdaq
- Market Cap
- CSLR 118.0M
- PBYI 138.4M
- IPO Year
- CSLR N/A
- PBYI N/A
- Fundamental
- Price
- CSLR $1.95
- PBYI $2.86
- Analyst Decision
- CSLR Buy
- PBYI Strong Buy
- Analyst Count
- CSLR 2
- PBYI 1
- Target Price
- CSLR $6.00
- PBYI $7.00
- AVG Volume (30 Days)
- CSLR 531.2K
- PBYI 334.3K
- Earning Date
- CSLR 04-23-2025
- PBYI 05-01-2025
- Dividend Yield
- CSLR N/A
- PBYI N/A
- EPS Growth
- CSLR N/A
- PBYI 37.78
- EPS
- CSLR N/A
- PBYI 0.62
- Revenue
- CSLR $40,797,000.00
- PBYI $230,468,000.00
- Revenue This Year
- CSLR $12.07
- PBYI N/A
- Revenue Next Year
- CSLR $254.23
- PBYI N/A
- P/E Ratio
- CSLR N/A
- PBYI $4.61
- Revenue Growth
- CSLR N/A
- PBYI N/A
- 52 Week Low
- CSLR $0.20
- PBYI $2.23
- 52 Week High
- CSLR $3.37
- PBYI $5.34
- Technical
- Relative Strength Index (RSI)
- CSLR 65.24
- PBYI 42.27
- Support Level
- CSLR $1.36
- PBYI $2.83
- Resistance Level
- CSLR $1.63
- PBYI $2.99
- Average True Range (ATR)
- CSLR 0.17
- PBYI 0.17
- MACD
- CSLR 0.05
- PBYI -0.01
- Stochastic Oscillator
- CSLR 93.33
- PBYI 50.00
About CSLR Complete Solaria Inc.
Complete Solaria Inc is a solar company with unique technology and end-to-end customer offering, which includes financing, project fulfilment and customer service. Complete Solaria's digital platform together with premium solar products enable one-stop service for clean energy needs for customers wishing to make the transition to a more energy-efficient lifestyle.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.